Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy(Hong Kong Children's Hospital)

N/A

Report date: 2024/06/18 20:00:07

Base Information

Drug NameAnti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy(Hong Kong Children's Hospital)
Drug Alias NameAnti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy(Hong Kong Children's Hospital)CUCART19 Therapy(Hong Kong Children's Hospital)Anti-CD19 CAR-T Therapy(Hong Kong Children's Hospital)Anti-CD19 chimeric antigen receptor modified T-cell (CAR-T) Therapy(Hong Kong Children's Hospital)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Non-HodgkinLeukemia, Lymphoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryHong Kong
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHong Kong Children'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesHong Kong Children'S Hospital
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-HodgkinLeukemia, Lymphoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A